Acceptance and adherence to chemoprevention among women at increased risk of breast cancer

Breast

Volumn 24, Issue 1, 2015, Pages 51-56

  Roetzheim, Richard G ^a,b   Lee, Ji Hyun ^c   Fulp, William ^a   Matos Gomez, Elizabeth ^a   Clayton, Elissa ^a   Tollin, Sharon ^a   Khakpour, Nazanin ^a   Laronga, Christine ^a   Lee, Marie Catherine ^a   Kiluk, John V ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Breast cancer; Breast cancer prevention; Chemoprevention; Lobular carcinoma in situ; Raloxifene; Tamoxifen

Indexed keywords

RALOXIFENE; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; ATYPICAL DUCTAL HYPERPLASIA; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONTROLLED STUDY; ETHNICITY; FAMILY HISTORY; FEMALE; HEALTH INSURANCE; HUMAN; HUMAN TISSUE; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; MEDICAL RECORD; MEDICATION COMPLIANCE; MENARCHE; OSTEOPOROSIS; PATIENT ATTITUDE; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT DURATION; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; MIDDLE AGED; RISK; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; LOGISTIC MODELS; MEDICATION ADHERENCE; MIDDLE AGED; RISK; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84920555150     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.11.006     Document Type: Article

References (36)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA - A Cancer J Clin 2014, 64:9-29.
2. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNatl Cancer Inst 1998, 90(18):1371-1388.
3. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295(23):2727-2741.
4. Barrett-Connor E., Mosca L., Collins P., Geiger M.J., Grady D., Kornitzer M., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. NEngl J Med 2006, 355(2):125-137.
5. Goss P.E., Ingle J.N., Ales-Martinez J.E., Cheung A.M., Chlebowski R.T., Wactawski-Wende J., et al. Exemestane for breast-cancer prevention in postmenopausal women. NEngl J Med 2011, 364(25):2381-2391.
6. Cuzick J., Sestak I., Forbes J.F., Dowsett M., Knox J., Cawthorn S., et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomized placebo-controlled trial. Lancet 2014, 383(9922):1041-1048.
7. U.S. Preventive Services Task Force 2014. Pages accessed at at October 28, 2014. http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrpv.htm.
8. Visvanathan K., Hurley P., Bantug E., Brown P., Col N.F., Cuzick J., et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. JClin Oncol 2013, 31(23):2942-2962.
9. Freedman A.N., Graubard B.I., Rao S.R., McCaskill-Stevens W., Ballard-Barbash R., Gail M.H. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. JNatl Cancer Inst 2003, 95(7):526-532.
10. Schmidt C. The breast cancer chemoprevention debate. JNatl Cancer Inst 2011, 103(22):1646-1647.
11. Kaplan C.P., Kim S.E., Wong S.T., Sawaya G.F., Walsh J.M., Perez-Stable E.J. Willingness to use tamoxifen to prevent breast cancer among diverse women. Breast Cancer Res Treat 2012, 133(1):357-366.
12. Melnikow J., Paterniti D., Azari R., Kuenneth C., Birch S., Kuppermann M., et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 2005, 103(10):1996-2005.
13. Ropka M.E., Keim J., Philbrick J.T. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. JClin Oncol 2010, 28(18):3090-3095.
14. Gail M.H., Brinton L.A., Byar D.P., Corle D.K., Green S.B., Schairer C., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. JNatl Cancer Inst 1989, 81(24):1879-1886.
15. Costantino J.P., Gail M.H., Pee D., Anderson S., Redmond C.K., Benichou J., et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. JNatl Cancer Inst 1999, 91(18):1541-1548.
16. Pankratz V.S., Hartmann L.C., Degnim A.C., Vierkant R.A., Ghosh K., Vachon C.M., et al. Assessment of the accuracy of the gail model in women with atypical hyperplasia. JClin Oncol 2008, 26(33):5374-5379.
17. Amir E., Evans D.G., Shenton A., Lalloo F., Moran A., Boggis C., et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. JMed Genet 2003, 40(11):807-814.
18. Chuba P.J., Hamre M.R., Yap J., Severson R.K., Lucas D., Shamsa F., et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. JClin Oncol 2005, 23(24):5534-5541.
19. Donnelly L.S., Evans D.G., Wiseman J., Fox J., Greenhalgh R., Affen J., et al. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer 2014, 110(7):1681-1687.
20. Layeequr Rahman R., Crawford S. Chemoprevention indication score: a user-friendly tool for prevention of breast cancer - pilot analysis. Breast 2009, 18(5):289-293.
21. Goldenberg V.K., Seewaldt V.L., Scott V., Bean G.R., Broadwater G., Fabian C., et al. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2007, 16(5):1032-1034.
22. Bober S.L., Hoke L.A., Duda R.B., Regan M.M., Tung N.M. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. JClin Oncol 2004, 22(24):4951-4957.
23. Evans D., Lalloo F., Shenton A., Boggis C., Howell A. Uptake of screening and prevention in women at very high risk of breast cancer. Lancet 2001, 358(9285):889-890.
24. Evans D.G., Harvie M., Bundred N., Howell A. Uptake of breast cancer prevention and screening trials. JMed Genet 2010, 47(12):853-855.
25. Owens W.L., Gallagher T.J., Kincheloe M.J., Ruetten V.L. Implementation in a large health system of a program to identify women at high risk for breast cancer. JOncol Pract 2011, 7(2):85-88.
26. Taylor R., Taguchi K. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med 2005, 3(3):242-247.
27. Ravdin P.M. The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention. Cancer Prev Res - Phila 2010, 3(6):686-688.
28. Fagerlin A., Dillard A.J., Smith D.M., Zikmund-Fisher B.J., Pitsch R., McClure J.B., et al. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast Cancer Res Treat 2011, 127(3):681-688.
29. Meiser B., Butow P., Price M., Bennett B., Berry G., Tucker K. Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer. JWomens Health - Larchmt 2003, 12(8):769-778.
30. Bastian L.A., Lipkus I.M., Kuchibhatla M.N., Weng H.H., Halabi S., Ryan P.D., et al. Women's interest in chemoprevention for breast cancer. Arch Intern Med 2001, 161(13):1639-1644.
31. Nelson H.D., Smith M.E., Griffin J.C., Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013, 158(8):604-614.
32. Cuzick J., Forbes J.F., Sestak I., Cawthorn S., Hamed H., Holli K., et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. JNatl Cancer Inst 2007, 99(4):272-282.
33. Murphy C.C., Bartholomew L.K., Carpentier M.Y., Bluethmann S.M., Vernon S.W. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 2012, 134(2):459-478.
34. Land S.R., Cronin W.M., Wickerham D.L., Costantino J.P., Christian N.J., Klein W.M., et al. Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res - Phila 2011, 4(9):1393-1400.
35. Waters E.A., Cronin K.A., Graubard B.I., Han P.K., Freedman A.N. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 2010, 19(2):443-446.
36. Waters E.A., McNeel T.S., Stevens W.M., Freedman A.N. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat 2012, 134(2):875-880.